Increased activity and improved outcome in unrelated donor haemopoietic cell transplants for acute myeloid leukaemia in Australia, 1992-2005

Internal Medicine Journal

Volumn 41, Issue 1 A, 2011, Pages 27-34

  Nivison Smith, I ^a   Dodds, A J ^b   Dunckley, H ^c   Ma, D D F ^b   Moore, J J ^b   Simpson, J M ^d   Szer, J ^f   Bradstock, K F ^e  

^a Australasian Bone Marrow Transplant Recipient Registry   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Acute; Haemopoietic; Leukaemia; Myeloid; Transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUSTRALIA; CANCER REGRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CAUSE OF DEATH; COMORBIDITY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251478436     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02262.x     Document Type: Article

References (26)

1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L etal. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-23.
2. Busca A, Anasetti C, Anderson G, Appelbaum FR, Buckner CD, Doney K etal. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994; 83: 3077-84.
3. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A etal. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404.
4. Bacher U, Haferlach C, Schnittger S, Kern W, Kroeger N, Zander AR etal. Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 2009; 43: 745-56.
5. Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M etal. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol 2009; 83: 99-107.
6. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Björkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009; 113: 3666-72.
7. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C etal. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23: 635-40.
8. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF etal. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1431-8.
9. Ringdén O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N etal. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-7.
10. Schetelig J, Bornhäuser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H etal. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183-91.
11. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687-705.
12. Lee SJ, Klein J, Haagenson M, Baxter-Lowe L, Confer DL, Eapen M etal. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-83.
13. Kollman C, Howe CWS, Anasetti C, Antin JH, Davies SM, Filipovich AH etal. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-51.
14. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T etal. Major histocompatibility complex Class I alleles and antigens in hematopoietic cell transplantation. N Engl J Med 2001; 345: 1794-800.
15. Wade JA, Hurley CK, Takemoto SK, Thompson J, Davies SM, Fuller TC etal. HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood 2007; 109: 4064-70.
16. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DDF, Moore JJ etal. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-12.
17. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P etal. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-69.
18. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J etal. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-8.
19. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S etal. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-9.
20. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K etal. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-91.
21. van Rood JJ, Oudshoorn M. Eleven million donors in bone marrow donors worldwide! Time for reassessment? Bone Marrow Transplant 2008; 41: 1-9.
22. Shan X, Xiao Y, Wang L, Lazaro AM, Hurley CK. Identification of 11 novel HLA alleles found during typing of unrelated registry donors in China. Tissue Antigens 2008; 71: 578-9.
23. Schmidt AH, Solloch UV, Baier D, Yazici B, Ozcan M, Stahr A etal. Criteria for initiation and evaluation of minority donor programs and application to the example of donors of Turkish descent in Germany. Bone Marrow Transplant 2009; 44: 405-12.
24. Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP etal. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114: 2606-16.
25. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J etal. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-7.
26. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P etal. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 2002; 117: 914-23.